Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

When he was 25, he learned that he had multiple sclerosis. He coped with the disease throughout a long career at several ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

Alchemab Therapeutics, a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...

Stephen Hawking would have turned 83 years old. Unfortunately, the world-renowned physicist passed away in 2018. Before his ...

Neurodegenerative diseases pose a serious threat to public health, with an increasing impact among the elderly population.

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other ...

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...